Taysha Gene Therapies (TSHA) Q3 2024 earnings summary

Executive summary

• Advanced TSHA-102 gene therapy for Rett Syndrome, achieving key clinical, regulatory, and manufacturing milestones, with ongoing Phase 1/2 REVEAL trials in adolescent/adult and pediatric patients showing favorable safety and early, sustained clinical improvements.

• Completed pivotal FDA meetings, aligning on regulatory pathway and trial design for TSHA-102, including use of natural history data and objective functional endpoints.

• Discontinued TSHA-120 for GAN and deprioritized other programs to focus resources on Rett syndrome.

• Received multiple regulatory designations for TSHA-102, including RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease status in the US and EU.

• Significant demand for trial participation from both adult and pediatric Rett Syndrome communities.

Financial highlights

• R&D expenses were $14.9M for Q3 2024, up from $11.8M in Q3 2023, mainly due to increased GMP batch activities and higher headcount.

• G&A expenses decreased to $7.9M from $8.6M year-over-year, primarily due to lower warrant issuance costs.

• Net loss for Q3 2024 was $25.5M ($0.10/share), a significant improvement from $117.1M ($0.93/share) in Q3 2023, mainly due to a prior non-cash warrant liability loss.

• Cash and equivalents totaled $157.7M as of September 30, 2024, expected to fund operations into Q4 2026.

• Non-cash impairment charge of $4.8M recorded for manufacturing facility and assets held for sale.

Outlook and guidance

• Expect to report longer-term low-dose and new high-dose data from both REVEAL trials in H1 2025.

• Ongoing discussions with FDA to finalize registrational study design and endpoints, aiming for alignment and disclosure in H1 2025.

• Current cash runway supports planned operations and development through Q4 2026.

• No product revenue expected in the near term; future revenue dependent on regulatory approval and commercialization.

• Anticipates increased R&D spending for Rett clinical trials and manufacturing; expects to require additional capital for future development and commercialization.